Drug Trial News

RSS

Phase 3 study: The efficacy of monovalent SARS-CoV-2 vaccine with AS03 adjuvant in adults

The effectiveness of a novel monovalent recombinant protein vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2023

Combination immunotherapy outperforms durvalumab monotherapy in neoadjuvant NSCLC

Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers at The University of Texas MD Anderson Cancer Center.

14 Sep 2023

Comparing HIV PrEP medications: Study explores hypertension risk in adults on TAF vs. TDF

The risk of hypertension and statin initiation in adults starting Human Immunodeficiency Virus Pre-exposure prophylaxis.

13 Sep 2023

Idrevadiloride in hypertonic saline improves lung function in people with primary ciliary dyskinesia, trial shows

Primary ciliary dyskenisia (PCD) is a rare genetic disease that causes the tiny hair-like filtration structures in the respiratory tract to stop working.

12 Sep 2023

Oxford University study administers first-ever vaccine against Crimean-Congo hemorrhagic fever

A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo hemorrhagic fever (CCHF) to volunteers for the first time.

11 Sep 2023

Buck Institute receives $3.5 million federal grant to lead clinical trial of ketone intervention in older adults

The Buck Institute for Research on Aging has received a $3.5 million federal grant to lead the first-ever double-blind, randomized, placebo-controlled clinical trial to understand the effects of ketone ester supplementation on frailty, a condition of vulnerability which develops following age-related decline in multiple physiological systems.

11 Sep 2023

CheckMate 227 trial: Nivolumab + ipilimumab shows remarkable six-year survival benefits in metastatic NSCLC

The International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore is set to witness a monumental breakthrough in the field of metastatic non-small cell lung cancer (NSCLC) treatment.

11 Sep 2023

Osimertinib plus chemotherapy shows significant PFS benefit in advanced EGFR-mutated NSCLC

Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.

11 Sep 2023

Durvalumab shows tolerable surgical safety profile in patients with resectable NSCLC

Adding perioperative durvalumab to neoadjuvant chemotherapy did not adversely impact surgery in patients with resectable NSCLC and was associated with a tolerable surgical safety profile, according to research presented today from the phase 3 AEGEAN trial at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore.

11 Sep 2023

Adagrasib shows durable clinical activity in KRAS-G12C-mutated NSCLC

The oral, selective KRAS G12C inhibitor The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.

11 Sep 2023

University of Birmingham and Acticor Biotech announce MHRA approval of LIBERATE clinical study

September 7th, 2023, the University of Birmingham and Acticor Biotech announce the full regulatory approval of LIBERATE clinical study.

9 Sep 2023

Phase I trial of senolytic therapy shows promise in Alzheimer's disease

Alzheimer's disease is the most common cause of dementia that affects more than 6.5 million Americans, according to the Alzheimer's Association.

8 Sep 2023

Broad-spectrum antibiotics linked to higher sepsis risk in neonates

A preprint presents evidence for the hypothesis that neonatal sepsis is linked to prenatal antibiotics.

7 Sep 2023

What are the efficacy and safety of psilocybin in patients with major depressive disorder?

The safety, timing, magnitude, and durability of the antidepressant psilocybin on patients with major depressive disorders.

4 Sep 2023

Combination of cediranib and lenalidomide does not improve outcomes in advanced thyroid cancer

Results of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show that adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) cediranib did not make a difference in outcomes for treating patients with an advanced form of thyroid cancer that develops from thyroid follicular cells called differentiated thyroid cancer (DTC).

1 Sep 2023

Amgen presents late-breaking Phase 2 olpasiran data at ESC 2023

Amgen today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose.

From AMGEN 1 Sep 2023

UQ-led clinical trial to test the effectiveness of diabetes drug for polycystic kidney disease

Patient recruitment is underway for a University of Queensland-led clinical trial to test the effectiveness of a diabetes drug to slow the progression of polycystic kidney disease (PKD).

30 Aug 2023

Can muvalaplin achieve safe and tolerable plasma concentrations adequate to reduce steady-state Lp(a) levels without modulating plasminogen activity in humans?

Researchers evaluated the tolerability, safety, pharmacodynamics, and pharmacokinetic properties of muvalaplin.

30 Aug 2023

Higher dose and shorter treatment of key antibiotic proven to be safe for TB patients

A higher dose and shorter treatment time of a cornerstone tuberculosis (TB) drug has proven to be safe for patients, according to a clinical trial led by researchers at St George's, University of London and results published in NEJM Evidence.

29 Aug 2023

ARAMIS trial finds no benefit of anakinra in acute myocarditis

The largest randomized controlled trial of patients with acute myocarditis has found that anakinra is safe but does not reduce complications. The late breaking research presented in a Hot Line session today at ESC Congress 2023.

29 Aug 2023

Previous
1
...
34
35
36
37
38
39
40
...
1162
Next

Drug Trial News

Phase 3 study: The efficacy of monovalent SARS-CoV-2 vaccine with AS03 adjuvant in adults

Combination immunotherapy outperforms durvalumab monotherapy in neoadjuvant NSCLC

Comparing HIV PrEP medications: Study explores hypertension risk in adults on TAF vs. TDF

Idrevadiloride in hypertonic saline improves lung function in people with primary ciliary dyskinesia, trial shows

Oxford University study administers first-ever vaccine against Crimean-Congo hemorrhagic fever

Buck Institute receives $3.5 million federal grant to lead clinical trial of ketone intervention in older adults

CheckMate 227 trial: Nivolumab + ipilimumab shows remarkable six-year survival benefits in metastatic NSCLC

Osimertinib plus chemotherapy shows significant PFS benefit in advanced EGFR-mutated NSCLC

Durvalumab shows tolerable surgical safety profile in patients with resectable NSCLC

Adagrasib shows durable clinical activity in KRAS-G12C-mutated NSCLC

University of Birmingham and Acticor Biotech announce MHRA approval of LIBERATE clinical study

Phase I trial of senolytic therapy shows promise in Alzheimer's disease

Broad-spectrum antibiotics linked to higher sepsis risk in neonates

What are the efficacy and safety of psilocybin in patients with major depressive disorder?

Combination of cediranib and lenalidomide does not improve outcomes in advanced thyroid cancer

Amgen presents late-breaking Phase 2 olpasiran data at ESC 2023

UQ-led clinical trial to test the effectiveness of diabetes drug for polycystic kidney disease

Can muvalaplin achieve safe and tolerable plasma concentrations adequate to reduce steady-state Lp(a) levels without modulating plasminogen activity in humans?

Higher dose and shorter treatment of key antibiotic proven to be safe for TB patients

ARAMIS trial finds no benefit of anakinra in acute myocarditis

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News